spacer
home > directory > CMAB Biopharma
PHARMACEUTICAL INDUSTRY DIRECTORY

CMAB Biopharma

CMAB Biopharma
CMAB Biopharma is a full service, pure play Contract Development and Manufacturing Organisation (CDMO), which provides bespoke solutions for mammalian cell culture derived antibodies and recombinant proteins.

Our mission is to be the biologic CDMO of choice for biopharma companies from around the world by leveraging our state-of-the-art manufacturing facility, our large-scale production capacity and our ability to meet international quality requirements.

Established in 2017 with strong financial backing from our three main shareholders (C-Bridge Capital, CD Capital and BioBay), our 10,500 m2 (112,980 ft2) facility is located just outside of Shanghai in Suzhou, China. We have grown rapidly in 18 months to 165 full time employees with international offices founded in Switzerland, Toronto and Singapore. Our senior management is composed of experts with experience working in large international biotechnology organisations such as Genentech, Eli Lilly, Pfizer, Amgen and Janssen as well as CDMOs such as Lonza, Wuxi, Therapure and MabPlex.

At CMAB biopharma, we provide expertise and experience in process and analytical development, drug substance (DS) and drug product (DP) cGMP manufacturing. Our process development and analytical development labs are fully equipped with the latest equipment including a mass spectrometer, which is used for protein characterisation. Our four parallel upstream suites offer flexible cGMP production scales using multiple single use bioreactors (SUBs) ranging from 200 to 2,000 L volumes. CMAB is currently installing a fully automated aseptic fill / finish line along with a lyophiliser, which will be capable of producing commercial quantities of DP in early 2020. Finally, we can also provide our clients with lot release testing and stability studies.

Our operational protocols and quality standards comply with FDA, EMA and NMPA guidelines, which enables CMAB Biopharma to produce cGMP material for global clients. In addition, our quality standards align to the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S), International Committee on Harmonization (ICH) and World Health Organisation (WHO) guidelines.

To learn more about CMAB Biopharma or to get in contact with us directly, please visit www.cmabbio.com or write to us at hello@cmabbio.com. We look forward to hearing from you.
phone +41 61 564 03 57
email hello@cmabbio.com
web www.cmabbio.com
email Teichgässlein 9, 4058 Basel, Switzerland
 
spacer

Member login

E-mail address:

Password:
Remember me

Industry Events

SCOPE Summit for Clinical Ops Executives

18-21 February 2020, Hyatt Regency, Orlando, Florida, US

Celebrating its 11th successful year, SCOPE Summit 2020 takes place February 18-21 in Orlando, FL. Over the course of four stimulating days of in-depth discussions in 20 different conferences, 3 plenary keynote sessions, the annual Participant Engagement Awards, and the ever-popular interactive breakout discussions, the programming focuses on advances and innovative solutions in all aspects of clinical trial planning, management and operations
More info >>

 
News and Press Releases

Gerresheimer opens a new plant for the production of pharmaceutical primary plastic packaging in China

Düsseldorf/Changzhou, December 11, 2019 – A new plant for producing plastic pharmaceutical packaging has been set up in the Chinese city of Changzhou to help satisfy the high demand for Gerresheimer’s primary packaging in China in the future. Today the new facility will be officially opened.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement